WO2004039842A3 - Humanized tissue factor antibodies - Google Patents

Humanized tissue factor antibodies Download PDF

Info

Publication number
WO2004039842A3
WO2004039842A3 PCT/DK2003/000741 DK0300741W WO2004039842A3 WO 2004039842 A3 WO2004039842 A3 WO 2004039842A3 DK 0300741 W DK0300741 W DK 0300741W WO 2004039842 A3 WO2004039842 A3 WO 2004039842A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
protein
human
humanized
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2003/000741
Other languages
French (fr)
Other versions
WO2004039842A2 (en
Inventor
Ivan Svendsen
Kristian Kjaergaard
Stefan Zahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to AU2003277832A priority Critical patent/AU2003277832A1/en
Publication of WO2004039842A2 publication Critical patent/WO2004039842A2/en
Publication of WO2004039842A3 publication Critical patent/WO2004039842A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

In one aspect, the invention provides non-immunogenic high affinity humanized antibodies against human TF, which antibodies inhibit the binding of coagulation factor VII/Vila. In another aspect, the invention provides novel and useful methods for selection of therapeutically effective humanized antibodies against human TF. In a further aspect the invention provides an isolated humanized antibody, that immunoreacts with an epitope P present on a protein, wherein the human framework amino acid sequences of said humanized antibody are derived from a human antibody, wherein said human antibody immunoreacts with an epitope H present on said protein, said epitope H comprising an amino acid residue at a particular position of said protein, which amino acid residue at this particular position of said protein is also comprised within the epitope P with which said humanized antibody immunoreacts.
PCT/DK2003/000741 2002-10-31 2003-10-31 Humanized tissue factor antibodies Ceased WO2004039842A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003277832A AU2003277832A1 (en) 2002-10-31 2003-10-31 Humanized tissue factor antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201661 2002-10-31
DKPA200201661 2002-10-31

Publications (2)

Publication Number Publication Date
WO2004039842A2 WO2004039842A2 (en) 2004-05-13
WO2004039842A3 true WO2004039842A3 (en) 2004-09-23

Family

ID=32187133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000741 Ceased WO2004039842A2 (en) 2002-10-31 2003-10-31 Humanized tissue factor antibodies

Country Status (2)

Country Link
AU (1) AU2003277832A1 (en)
WO (1) WO2004039842A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516564A (en) * 2003-01-22 2006-07-06 ノボ　ノルディスク　アクティーゼルスカブ TF binding agents and their use
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US20050031615A1 (en) * 2003-05-30 2005-02-10 Anderson G. Mark Method of inhibiting tumor growth with anti-tissue factor antibodies
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
UA109633C2 (en) * 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
BR112012031727B1 (en) 2010-06-15 2022-03-29 Genmab A/S DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION, AND, USE OF DRUG-ANTIBODY CONJUGATE
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
CN111727075B (en) * 2017-11-27 2024-04-05 普渡制药公司 Humanized antibodies targeting human tissue factor
TW202506732A (en) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN115348971A (en) * 2020-03-30 2022-11-15 国立研究开发法人国立癌症研究中心 Antibody-drug conjugates

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040921A1 (en) * 1995-06-07 1996-12-19 Ortho Farmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
WO1997018838A1 (en) * 1995-11-21 1997-05-29 Athena Neurosciences, Inc. Therapeutic uses of humanized antibodies against alpha-4 integrin
WO1998001757A1 (en) * 1996-07-08 1998-01-15 Cambridge Antibody Technology Limited Labelling and selection of molecules
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
WO2003037911A2 (en) * 2001-10-29 2003-05-08 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
WO1996040921A1 (en) * 1995-06-07 1996-12-19 Ortho Farmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
WO1997018838A1 (en) * 1995-11-21 1997-05-29 Athena Neurosciences, Inc. Therapeutic uses of humanized antibodies against alpha-4 integrin
WO1998001757A1 (en) * 1996-07-08 1998-01-15 Cambridge Antibody Technology Limited Labelling and selection of molecules
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
WO2003037911A2 (en) * 2001-10-29 2003-05-08 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANK KOLBINGER ET AL: "Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies", PROTEIN ENGINEERING, vol. 6, no. 8, 1993, pages 971 - 980, XP002271768 *
LEONARD PRESTA ET AL: "Generation of a Humanized, High Affinity Anti-tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic", THROMB HAEMOST, vol. 85, 2001, pages 379 - 389, XP002271767 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Also Published As

Publication number Publication date
AU2003277832A1 (en) 2004-05-25
WO2004039842A2 (en) 2004-05-13
AU2003277832A8 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2006036291A3 (en) Antibodies directed against amyloid-beta peptide and methods using same
WO2000005249A3 (en) Synthetic peptides and methods of use for autoimmune disease therapies
EP1693384A3 (en) Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof
WO2004039842A3 (en) Humanized tissue factor antibodies
WO2006033702A3 (en) Anti-cd154 antibodies
NZ593068A (en) IL-18 antibody
WO2003068920A3 (en) Humanized gm-csf antibodies
UA86605C2 (en) Antibody comprising a variant fc region
WO2002092771A3 (en) Specific binding proteins and uses thereof
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2005063816A3 (en) Monovalent antibody fragments useful as therapeutics
IL210454A (en) Antibody against a cytokine zcytor17 ligand
WO2006017325A3 (en) Aav vector compositions and methods for enhanced expression of immunoglobulins the same
EP2343318A3 (en) Antibodies binding to a C-terminal fragment of apolipoprotein E
WO2003046204A8 (en) Humanized collagen antibodies and related methods
WO2004013161A3 (en) Peptide aggregates
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
MX2007000103A (en) Universal antibody libraries.
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2003079750A3 (en) ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
WO2003072602A3 (en) Protein complexes and methods for their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP